Enterococcus faecium Infections - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 126 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Enterococcus faecium Infections - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Enterococcus Faecium Infections - Pipeline Review, H2 2015', provides an overview of the Enterococcus Faecium Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Enterococcus Faecium Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Enterococcus Faecium Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Enterococcus Faecium Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Enterococcus Faecium Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Enterococcus faecium Infections Overview 10
Therapeutics Development 11
Pipeline Products for Enterococcus faecium Infections - Overview 11
Pipeline Products for Enterococcus faecium Infections - Comparative Analysis 12
Enterococcus faecium Infections - Therapeutics under Development by Companies 13
Enterococcus faecium Infections - Therapeutics under Investigation by Universities/Institutes 15
Enterococcus faecium Infections - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Enterococcus faecium Infections - Products under Development by Companies 19
Enterococcus faecium Infections - Products under Investigation by Universities/Institutes 21
Enterococcus faecium Infections - Companies Involved in Therapeutics Development 22
Alchemia Limited 22
Alvogen Korea 23
Aphios Corporation 24
BioSource Pharm, Inc. 25
Cellceutix Corporation 26
ContraFect Corporation 27
Helix BioMedix, Inc. 28
Hsiri Therapeutics, LLC 29
LegoChem Biosciences, Inc 30
Lytix Biopharma AS 31
Melinta Therapeutics, Inc 32
MGB Biopharma Limited 33
Microbiotix, Inc. 34
MicuRx Pharmaceuticals, Inc. 35
NovaBay Pharmaceuticals, Inc. 36
Novan, Inc. 37
NovoBiotic Pharmaceuticals, LLC 38
Omnia Molecular Ltd. 39
Oragenics, Inc. 40
Sealife PHARMA GMBH 41
Sentinella Pharmaceuticals, Inc. 42
Sumitomo Dainippon Pharma Co., Ltd. 43
TAXIS Pharmaceuticals, Inc. 44
Wockhardt Limited 45
Enterococcus faecium Infections - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Target 47
Assessment by Mechanism of Action 49
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 55
auriclosene - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
brilacidin tetrahydrochloride - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
BSPC-728 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CF-304 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
chrysophaentin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
closthioamide - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Epimerox - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
HB-1345 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
HT-01 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
HT-02 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
IBN-1 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
LCB-010371 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
LCB-010699 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
LTX-109 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Marinus - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
MBX-1162 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
MGBBP-3 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MRX-I - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
MRX-IV - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
MU-1140 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
NAI-107 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
NAI-603 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
NVN-1000 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
OM-011818 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
RX-05 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
RXP-873 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
SLP-0904 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
SLP-0905 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
SM-295291 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
SM-369926 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Small Molecule to Inhibit Glycosyltransferase for Bacterial Infection - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Small Molecules for MRSA and Vancomycin-Resistant Enterococcus Faecium Infections - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
SP-2078 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Teixobactin - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
WCK-4086 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Enterococcus faecium Infections - Recent Pipeline Updates 101
Enterococcus faecium Infections - Dormant Projects 119
Enterococcus faecium Infections - Discontinued Products 121
Enterococcus faecium Infections - Product Development Milestones 122
Featured News & Press Releases 122
Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I 122
Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project 122
Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140 123
Sep 12, 2012: NovaBay Pharma Announces Data From New Study Demonstrating Chemical Impact Of N-chlorotaurine And NVC-422 On Bacterial Toxins 123
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 124
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I 124
Appendix 125
Methodology 125
Coverage 125
Secondary Research 125
Primary Research 125
Expert Panel Validation 125
Contact Us 125
Disclaimer 12

List of Tables

Number of Products under Development for Enterococcus faecium Infections, H2 2015 11
Number of Products under Development for Enterococcus faecium Infections - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Comparative Analysis by Unknown Stage Development, H2 2015 18
Products under Development by Companies, H2 2015 19
Products under Development by Companies, H2 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2015 21
Enterococcus faecium Infections - Pipeline by Alchemia Limited, H2 2015 22
Enterococcus faecium Infections - Pipeline by Alvogen Korea, H2 2015 23
Enterococcus faecium Infections - Pipeline by Aphios Corporation, H2 2015 24
Enterococcus faecium Infections - Pipeline by BioSource Pharm, Inc., H2 2015 25
Enterococcus faecium Infections - Pipeline by Cellceutix Corporation, H2 2015 26
Enterococcus faecium Infections - Pipeline by ContraFect Corporation, H2 2015 27
Enterococcus faecium Infections - Pipeline by Helix BioMedix, Inc., H2 2015 28
Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics, LLC, H2 2015 29
Enterococcus faecium Infections - Pipeline by LegoChem Biosciences, Inc, H2 2015 30
Enterococcus faecium Infections - Pipeline by Lytix Biopharma AS, H2 2015 31
Enterococcus faecium Infections - Pipeline by Melinta Therapeutics, Inc, H2 2015 32
Enterococcus faecium Infections - Pipeline by MGB Biopharma Limited, H2 2015 33
Enterococcus faecium Infections - Pipeline by Microbiotix, Inc., H2 2015 34
Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2015 35
Enterococcus faecium Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2015 36
Enterococcus faecium Infections - Pipeline by Novan, Inc., H2 2015 37
Enterococcus faecium Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2015 38
Enterococcus faecium Infections - Pipeline by Omnia Molecular Ltd., H2 2015 39
Enterococcus faecium Infections - Pipeline by Oragenics, Inc., H2 2015 40
Enterococcus faecium Infections - Pipeline by Sealife PHARMA GMBH, H2 2015 41
Enterococcus faecium Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H2 2015 42
Enterococcus faecium Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 43
Enterococcus faecium Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H2 2015 44
Enterococcus faecium Infections - Pipeline by Wockhardt Limited, H2 2015 45
Assessment by Monotherapy Products, H2 2015 46
Number of Products by Stage and Target, H2 2015 48
Number of Products by Stage and Mechanism of Action, H2 2015 50
Number of Products by Stage and Route of Administration, H2 2015 52
Number of Products by Stage and Molecule Type, H2 2015 54
Enterococcus faecium Infections Therapeutics - Recent Pipeline Updates, H2 2015 101
Enterococcus faecium Infections - Dormant Projects, H2 2015 119
Enterococcus faecium Infections - Dormant Projects (Contd..1), H2 2015 120
Enterococcus faecium Infections - Discontinued Products, H2 2015 121